Abstract
Many people take the antiretroviral drugs tenofovir and emtricitabine to prevent and treat HIV infection. Hughes et al. show that these medications induce genes and proteins associated with type I/III interferon pathways in the gut. This effect may contribute to HIV inhibition but could also cause chronic immune activation.
Original language | English (US) |
---|---|
Article number | 100096 |
Journal | Cell Reports Medicine |
Volume | 1 |
Issue number | 6 |
DOIs | |
State | Published - Sep 22 2020 |
Externally published | Yes |
Keywords
- ART
- HIV
- HIV cure
- ISG15
- antiretroviral treatment
- chronic immune activation
- gut
- interferon
- tenofovir
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Fingerprint
Dive into the research topics of 'Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. / Hughes, Sean M.; Levy, Claire N.; Calienes, Fernanda L.; Stekler, Joanne D.; Pandey, Urvashi; Vojtech, Lucia; Berard, Alicia R.; Birse, Kenzie; Noël-Romas, Laura; Richardson, Brian; Golden, Jackelyn B.; Cartwright, Michael; Collier, Ann C.; Stevens, Claire E.; Curlin, Marcel E.; Holtz, Timothy H.; Mugo, Nelly; Irungu, Elizabeth; Katabira, Elly; Muwonge, Timothy; Lama, Javier R.; Baeten, Jared M.; Burgener, Adam; Lingappa, Jairam R.; McElrath, M. Juliana; Mackelprang, Romel; McGowan, Ian; Cranston, Ross D.; Cameron, Mark J.; Hladik, Florian.
In: Cell Reports Medicine, Vol. 1, No. 6, 100096, 22.09.2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection
AU - Hughes, Sean M.
AU - Levy, Claire N.
AU - Calienes, Fernanda L.
AU - Stekler, Joanne D.
AU - Pandey, Urvashi
AU - Vojtech, Lucia
AU - Berard, Alicia R.
AU - Birse, Kenzie
AU - Noël-Romas, Laura
AU - Richardson, Brian
AU - Golden, Jackelyn B.
AU - Cartwright, Michael
AU - Collier, Ann C.
AU - Stevens, Claire E.
AU - Curlin, Marcel E.
AU - Holtz, Timothy H.
AU - Mugo, Nelly
AU - Irungu, Elizabeth
AU - Katabira, Elly
AU - Muwonge, Timothy
AU - Lama, Javier R.
AU - Baeten, Jared M.
AU - Burgener, Adam
AU - Lingappa, Jairam R.
AU - McElrath, M. Juliana
AU - Mackelprang, Romel
AU - McGowan, Ian
AU - Cranston, Ross D.
AU - Cameron, Mark J.
AU - Hladik, Florian
N1 - Funding Information: We wish to express gratitude to all of the study volunteers for their participation. We are grateful to Max Abou and Lauren Girard for proteomic wet lab support as well as Stuart McCorrister and Garrett Westmacott for mass spectrometry technical support. We acknowledge the Fred Hutchinson Experimental Histopathology (Sunni Farley, Savanh Chanthaphavong, and Li-Ya Huang) and Genomics (Cassie Sather and Crissa Bennett) core facilities for their assistance. This work was funded by NIH R01AI116292 (to F.H.), NIH R01AI111738 (to J.R. Lingappa), the Bill and Melinda Gates Foundation grant no. 47674 (to J.M.B.), NIH R01AI134293 (to R.M.), NIH AI027757 (to J.M.B.), NIH AI069481 (to A.C.C. and M.J.M.). M.J.C. and I.M. were supported by the Microbicide Trials Network ( UM1AI068633 , Sharon Hillier, principal investigator). A.B. was supported by the Canadian Institutes of Health Research ( 154042 ) and NIH ( R01DK112254 ). This work was also supported by the Emory-Centers for Disease Control and Prevention (CDC) HIV/AIDS Clinical Trials Unit Grant award no. UM1AI069418 from the NIH ( National Institute of Allergy and Infectious Diseases [NIAID]).The ddPCR portion of this work was supported by a grant from the James B. Pendleton Charitable Trust . The National Cancer Institute (NCI) 5 P30 CA015704-44 Cancer Center Support Grant supported the Fred Hutchinson Experimental Histopathology core facility. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies or the CDC. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The corresponding author had full access to all of the data in the study and had the final responsibility for the decision to submit for publication. Funding Information: We wish to express gratitude to all of the study volunteers for their participation. We are grateful to Max Abou and Lauren Girard for proteomic wet lab support as well as Stuart McCorrister and Garrett Westmacott for mass spectrometry technical support. We acknowledge the Fred Hutchinson Experimental Histopathology (Sunni Farley, Savanh Chanthaphavong, and Li-Ya Huang) and Genomics (Cassie Sather and Crissa Bennett) core facilities for their assistance. This work was funded by NIH R01AI116292 (to F.H.), NIH R01AI111738 (to J.R. Lingappa), the Bill and Melinda Gates Foundation grant no. 47674 (to J.M.B.), NIH R01AI134293 (to R.M.), NIH AI027757 (to J.M.B.), NIH AI069481 (to A.C.C. and M.J.M.). M.J.C. and I.M. were supported by the Microbicide Trials Network (UM1AI068633, Sharon Hillier, principal investigator). A.B. was supported by the Canadian Institutes of Health Research (154042) and NIH (R01DK112254). This work was also supported by the Emory-Centers for Disease Control and Prevention (CDC) HIV/AIDS Clinical Trials Unit Grant award no. UM1AI069418 from the NIH (National Institute of Allergy and Infectious Diseases [NIAID]).The ddPCR portion of this work was supported by a grant from the James B. Pendleton Charitable Trust. The National Cancer Institute (NCI) 5 P30 CA015704-44 Cancer Center Support Grant supported the Fred Hutchinson Experimental Histopathology core facility. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies or the CDC. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The corresponding author had full access to all of the data in the study and had the final responsibility for the decision to submit for publication. Data Curation, S.M.H. C.N.L. A.R.B. K.B. L.N.R. B.R. J.B.G. and M.C.; Formal Analysis, S.M.H. and C.N.L.; Funding Acquisition, J.M.B. J.R. Lingappa, I.M. R.D.C. and F.H.; Investigation, S.M.H. C.N.L. F.L.C. U.P. A.R.B. K.B. L.N.-R. B.R. J.B.G. and M.C.; Methodology, S.M.H. U.P. and F.H.; Project Administration, S.M.H. and F.H.; Resources, F.L.C. J.D.S. A.C.C. C.E.S. M.E.C. T.H.H. N.M. E.I. E.K. T.M. J.R. Lama, J.M.B. J.R. Lingappa, R.M. I.M. and R.D.C.; Software, S.M.H. and C.N.L.; Supervision, J.M.B. A.B. J.R. Lingappa, M.J.M. M.J.C. and F.H.; Visualization, S.M.H.; Writing ? Original Draft, S.M.H. and F.H.; Writing ? Review & Editing, S.M.H. C.N.L. J.D.S. L.V. B.R. J.B.G. A.C.C. M.E.C. T.H.H. J.M.B. J.R. Lingappa, I.M. R.D.C. M.J.C. and F.H. J.M.B. is on the advisory boards of Gilead Sciences, Merck, and Janssen. I.M. is the Chief Medical Officer of Orion Biotechnology. All of the other authors declare no competing interests. Publisher Copyright: © 2020 The Author(s)
PY - 2020/9/22
Y1 - 2020/9/22
N2 - Many people take the antiretroviral drugs tenofovir and emtricitabine to prevent and treat HIV infection. Hughes et al. show that these medications induce genes and proteins associated with type I/III interferon pathways in the gut. This effect may contribute to HIV inhibition but could also cause chronic immune activation.
AB - Many people take the antiretroviral drugs tenofovir and emtricitabine to prevent and treat HIV infection. Hughes et al. show that these medications induce genes and proteins associated with type I/III interferon pathways in the gut. This effect may contribute to HIV inhibition but could also cause chronic immune activation.
KW - ART
KW - HIV
KW - HIV cure
KW - ISG15
KW - antiretroviral treatment
KW - chronic immune activation
KW - gut
KW - interferon
KW - tenofovir
UR - http://www.scopus.com/inward/record.url?scp=85096573619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096573619&partnerID=8YFLogxK
U2 - 10.1016/j.xcrm.2020.100096
DO - 10.1016/j.xcrm.2020.100096
M3 - Article
C2 - 33015651
AN - SCOPUS:85096573619
VL - 1
JO - Cell Reports Medicine
JF - Cell Reports Medicine
SN - 2666-3791
IS - 6
M1 - 100096
ER -